The U.S. Food and Drug Administration (FDA) recently approved Sanofi-Aventis’ Sarclisa (isatuximab-irfc) for the treatment of adult patients with multiple myeloma. Isatuximab-irfc was previously…
A recent study published in the Medical Journal of Australia examined the “proportion of cancer diagnoses in Australia that might reasonably be attributed to…
The U.S. Food and Drug Administration (FDA) recently approved Epizyme, Inc’s tazemetostat (TAZVERIK) for the treatment of adult and pediatric patients with metastatic or…
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to Global Blood Therapeutics’ voxelotor (Oxbryta), a treatment for adults and pediatric patients…
Innovative study designs examine implementation and generate new knowledge. Takeaways: Some organizations struggle to meet Magnet® nurse research requirements. Many research efforts result in…
The Food and Drug Administration (FDA) has recently granted accelerated approval to BeiGene’s mantle cell lymphoma (MCL) oral therapy, zanubritinib (BRUKINSA). (more…)
The U.S. Food and Drug Administration (FDA) recently approved Sanofi-Aventis’ Sarclisa (isatuximab-irfc) for the treatment of adult patients with multiple myeloma. Isatuximab-irfc…
The U.S. Food and Drug Administration (FDA) recently approved Epizyme, Inc’s tazemetostat (TAZVERIK) for the treatment of adult and pediatric patients with…
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to Global Blood Therapeutics’ voxelotor (Oxbryta), a treatment for adults and…
Innovative study designs examine implementation and generate new knowledge. Takeaways: Some organizations struggle to meet Magnet® nurse research requirements. Many research efforts…
The Food and Drug Administration (FDA) has recently granted accelerated approval to BeiGene’s mantle cell lymphoma (MCL) oral therapy, zanubritinib (BRUKINSA). (more…)